1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Antiemetic Drugs: World Industry and Market Analysis 2014-2024

Report Details

Treatments for nausea and vomiting – explore business trends, R&D, and revenue forecasts
What’s the future of treating nausea and vomiting? For those medicines you get sales predictions, also exploring research and development. Those treatments hold high potential. There you assess results, progress, therapies, and opportunities.
Visiongain’s new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. Discover business potentials – trends, technologies, and new drugs.
Read on to explore anti-nausea and anti-vomiting therapies, seeing their potential revenue.

Forecasts to 2024 and other analyses explain and predict that pharma market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find results, growth rates, market shares, and discussions.
Also you explore research and development (R&D). That study gives 41 tables, 48 charts, and an interview with a company. There find how you could benefit your authority and save time, staying ahead.
That study lets you assess the future of treating nausea and vomiting – especially in cancer treatment – exploring rising needs and demands. You find where opportunities and money lie. See, from 2014, where best selling prospects exist.
And the following sections show how that new investigation benefits your research, analyses and decisions.

Forecasting of that world market and its main segments

In our report you discover overall world revenue to 2024 for antiemetic medicines, with discussions.
You also find individual revenue predictions to 2024 for four submarkets at world level – drug classes:
- 5-HT3 antagonists
- Cannabinoids
- Dopamine antagonists
- Other agents (grouped).
There you assess outlooks for expansion in trade, hearing where you could gain. That work investigates therapies, uses, and rising sales. Our study also explores competition.
There you hear what’s happening for developers, producers, and sellers of antiemetic agents, understanding challenges, trends, and rising sales.
That work also splits its overall world market into products.

Predictions of leading treatments’ sales

How will drugs perform to 2024 at world level? Our study forecasts individual revenues of eight top products:
- Palonosetron
- Ondansetron
- Granisetron
- Dolasetron
- Dronabinol
- Nabilone
- Metoclopramide
- Domperidone.
There you find medicines and years with highest predicted sales. You also examine competitors. See, then, what’s happening, understanding, challenges, trends, and outlooks.
The new study also gives geographical revenue predictions.

Healthcare in national markets – what outlooks for that business?

In developed and developing countries, many opportunities for developers, producers, and sellers of antiemetic medicines will occur from 2014 to 2024. See where and how.
Our analyses show individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Japan
- Germany, France, UK, Italy, and Spain (EU5)
- Brazil, Russia, India, and China (BRIC nations).
There you find countries with highest revenues, demand, and potential sales growth. Explore progress, needs and opportunities.
Also what events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and R&D.

Market forces and issues – developments, challenges, and events influencing business

The report also explains issues, forces, and events affecting the antiemetic drugs industry and market from 2014, including these:
- Emesis and its pharmacological management – pathways and targets
- Future of serotonin (5-HT3) antagonists – existing and new therapies
- Demand for antiemetics in post-operativ

Table Of Contents

Antiemetic Drugs: World Industry and Market Analysis 2014-2024
1. Overview of Report
1.1 Antiemetic Drug Treatments: World Market Review
1.2 Content of Report Chapters
1.3 Research and Analysis Methods

2. Introduction to Emesis and Antiemetic Drugs
2.1 What is Emesis?
2.1.1 The Process of Emesis: The Role of the Vomiting Centre
2.2 Causes and Complications of Vomiting Vary
2.2.1 Most Common Triggers of Vomiting
2.3 Diagnosing Emesis: Multidisciplinary Approach Required
2.4 Treating Emesis and the Approach to Pharmacological Management
2.4.1 Serotonin (5-HT3) Antagonists: Gold Standard Treatment
2.4.2 Cannabinoids: Controversial Choice, But Interest Remains
2.4.3 Dopamine Antagonists: Effective in Post-Operative Setting
2.4.4 Other Therapies

3. The Global Antiemetic Drug Market, 2014-2024
3.1 The Global Antiemetic Drug Market, 2013
3.1.1 Leading Antiemetic Drugs, 2013
3.2 The Global Antiemetic Drug Market: Revenue Forecast, 2014-2024
3.2.1 What Will Drive The Global Antiemetic Drug Market Between 2014 and 2024?
3.2.1.1 Growing Incidence of Cancer and Other Diseases
3.2.1.2 Increased Research Efforts Focused on New Therapies
3.2.1.3 Identifying New Drug Targets Through Technology
3.2.1.4 Launch of Novel Delivery Methods to Encourage Patient Compliance
3.2.2 What Factors are Likely to Restrain the Global Antiemetic Drug Market Between 2014 and 2024?
3.2.2.1 Improvements Needed in Design of Antiemetic Clinical Trials
3.2.2.2 High Cost of Alternative Animal Models
3.3 How Will the Market Shares of Leading Antiemetic Drug Classes Change From 2014-2024?

4. The 5-HT3 Antagonists Drug Market, 2014-2024
4.1 The 5-HT3 Antagonists Drug Market, 2013
4.2 The 5-HT3 Antagonists Drug Market: Revenue Forecast, 2014-2024
4.2.1 The 5-HT3 Antagonists Drug Market: Industry Trends, 2014-2024
4.3 The 5-HT3 Antagonists Drug Market: Revenue Forecasts of Leading Drugs, 2014-2024
4.3.1 Palonosetron (Aloxi®): Revenue Forecast, 2014-2024
4.3.2 Ondansetron (Zofran®): Revenue Forecast, 2014-2024
4.3.3 Granisetron (Sancuso®): Revenue Forecast, 2014-2024
4.3.4 Dolasetron (Anzemet®): Revenue Forecast, 2014-2024
4.4 How Will Market Shares of Leading 5-HT3 Antagonist Drugs Change from 2014-2024?

5. The Cannabinoids Drug Market, 2014-2024
5.1 The Cannabinoids Drug Market, 2013
5.2 The Cannabinoids Drug Market: Revenue Forecast, 2014-2024
5.2.1 The Cannabinoids Drug Market: Industry Trends, 2014-2024
5.3 The Cannabinoids Drug Market: Revenue Forecast by Leading Drugs, 2014-2024
5.3.1 Dronabinol (Marinol®): Revenue Forecast, 2014-2024
5.3.2 Nabilone (Cesamet®): Revenue Forecast, 2014-2024
5.4 How Will the Market Shares of Leading Cannabinoid Drugs Change from 2014-2024?

6. The Dopamine Antagonists Drug Market, 2014-2024
6.1 The Dopamine Antagonists Drug Market, 2013
6.2 The Dopamine Antagonists Drug Market: Revenue Forecast, 2014-2024
6.2.1 The Dopamine Antagonists Drug Market: Industry Trends, 2014-2024
6.3 The Dopamine Antagonists Drug Market: Revenue Forecast by Leading Drugs, 2014-2024
6.3.1 Metoclopramide (Reglan®): Revenue Forecast, 2014-2024
6.3.2 Domperidone (Motilium®): Revenue Forecast, 2014-2024
6.4 How Will Market Shares of Leading Dopamine Antagonist Drugs Change from 2014-2024?

7. Leading National Markets for Antiemetic Drugs, 2014-2024
7.1 Leading National Markets for Antiemetic Drugs, 2013
7.2 The Global Antiemetic Drug Market: Revenue Forecasts by Region, 2014-2024
7.3 The US Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.3.1 Novel Drug Formulation to Increase Compliance
7.4 The Antiemetic Drug Market in Leading EU Countries (EU5), 2013
7.4.1 The Antiemetic Drug Market in the EU5: Revenue Forecasts by Country, 2014-2024
7.4.1.1 The German Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.2 The French Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.3 The UK Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.4 The Italian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.4.1.5 The Spanish Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.5 The Japanese Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.6 The Russian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.7 The Chinese Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.7.1 Strong Incentives Prompt Entry of New Companies
7.7.2 Multi-Billion Dollar Investment to Improve Healthcare
7.8 The Indian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.8.1 Difficulties in Drug Distribution May Restrict Market
7.9 The Brazilian Antiemetic Drug Market: Revenue Forecast, 2014-2024
7.9.1 Restrictions on Foreign Companies May Stifle Market Growth

8. The Antiemetic Drug Market: RandD Pipeline, 2014
8.1 Discovering New Treatments and Molecular Targets
8.2 Targeting Serotonin: Expanding on the Clinical Success of 5-HT3 Antagonists
8.2.1 Sustol (APF-530; Heron Therapeutics): Enhanced Duration of Action
8.2.2 RHB-102 (RedHill Biopharma): Consistent Bioequivalency with Marketed Therapy
8.2.3 ETI-385 (Epiomed): Aiming to Target Multiple Emesis Pathways
8.3 Cannabinoids: RandD Pipeline Developments
8.3.1 Dronabinol Oral Solution (INSYS Therapeutics): Improved Bioavailability
8.4 Dopamine Antagonists: RandD Pipeline Developments
8.4.1 APD421 (Acacia Pharma): New Indication for Drug?
8.4.2 APD403 (Acacia Pharma): Potential Market Leader?
8.5 Other Novel Drugs Under Development
8.5.1 NK1 Receptor Antagonists
8.5.1.1 Netupitant-Palonosetron (Helsinn Healthcare): Dual Drug Combination
8.5.1.2 Rolapitant (OPKO Health/TESARO): Therapy Offering Prolonged, 5-day Effect
8.5.1.3 Vestipitant (GW597599; GSK): Applications in Numerous Therapeutic Areas?
8.5.2 Antihistamines
8.5.2.1 CL-108 (Charleston Laboratories): Targeting Emesis and Pain
8.5.3 Non-Pharmacological Therapies
8.5.3.1 Zindol (Aphios Corporation): Ginger-based Therapy

9. World Antiemetic Drug Market: Industry Trends, 2014-2024
9.1 SWOT Analysis of the Global Antiemetic Drug Market, 2014-2024
9.2 Strengths
9.2.1 The Drive to Discover a Universal Therapy
9.2.2 Varied Market Landscape Containing Big and Small Players
9.3 Weaknesses
9.3.1 Antiemetic Trials Need Overhaul
9.4 Opportunities
9.4.1 Global Increase in Cancer Prevalence
9.4.2 Secondary Indications Encourage Companies to Enter Market
9.5 Threats
9.5.1 Concerns of Cardiac Side Effects of Market-Leading Drugs
9.5.2 Wearable Devices: Stimulating Neural Emesis Pathways
9.6 STEP Analysis of the Global Antiemetic Drug Market, 2014-2024
9.6.1 Social Factors
9.6.2 Technological Advances
9.6.3 Economic Pressures
9.6.4 Political Issues

10. Research Interview
10.1 Interview with a Respondent from a Company Marketing Antiemetic Therapies
10.1.1 The Current Antiemetic Drug Market and Demand in the Asia-Pacific Region
10.1.2 Market Competition and Common Diseases Triggering Emesis
10.1.3 Current and Future Directions for Antiemetic Therapy

11. Conclusions
11.1 The Global Antiemetic Drug Market - Current Status
11.2 Outlook for the Global Antiemetic Drugs Market, 2014-2024
11.2.1 5-HT3 Antagonists Will Continue to Dominate the Market
11.2.2 Regional Outlook for the Antiemetic Drugs Market, 2014-2024


List of Tables
Table 1.1 Common Abbreviations Used in this Report
Table 2.1 Commonly Prescribed Antiemetic Medications, 2014
Table 3.1 The Global Antiemetic Drug Market: Revenue ($m) and Market Share (%) by Drug Class, 2013
Table 3.2 Leading Antiemetic Drugs: Revenue ($m) and Market Share (%) by Drug, 2013
Table 3.3 The Global Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Drug Class, 2014-2024
Table 3.4 The Global Antiemetic Market: Market Shares (%) by Drug Class, 2014-2024
Table 4.1 The 5-HT3 Antagonists Drug Market: Revenue ($m) and Market Share (%) by Leading Drug, 2013
Table 4.2 The 5-HT3 Antagonists Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024
Table 4.3 Palonosetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 4.4 Ondansetron: Revenue Forecast ($m, AGR, CAGR %), 2014-2024
Table 4.5 Granisetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 4.6 Dolasetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 4.7 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2014-2024
Table 5.1 The Cannabinoids Drug Market: Revenue ($m) and Market Shares (%) by Leading Drug, 2013
Table 5.2 The Cannabinoids Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024
Table 5.3 Dronabinol: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 5.4 Nabilone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 5.5 The Cannabinoids Drug Market: Market Share (%) by Drug, 2014-2024
Table 6.1 The Dopamine Antagonists Drug Market: Revenues ($m) and Market Shares (%) by Leading Drug, 2013
Table 6.2 The Dopamine Antagonists Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024
Table 6.3 Metoclopramide: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 6.4 Domperidone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 6.5 The Dopamine Antagonists: Market Shares (%) by Drug, 2014-2024
Table 7.1 The Global Antiemetic Drug Market: Revenues ($m) and Market Shares (%) by Region, 2013
Table 7.2 The Global Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2014-2024
Table 7.3 The US Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.4 The EU5 Antiemetic Drug Market: Revenue ($m), EU5 Market Share (%) and Global Market Share (%) by Country, 2013
Table 7.5 The EU5 Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) for Leading Countries, 2014-2024
Table 7.6 The German Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.7 The French Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.8 The UK Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.9 The Italian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.10 The Spanish Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.11 The Japanese Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.12 The Russian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.13 The Chinese Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.14 The Indian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 7.15 The Brazilian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
Table 9.1 SWOT Analysis of the World Antiemetic Drugs Market, 2014-2024
Table 11.1 The World Antiemetic Drugs Market: Revenue Forecasts ($m, AGR %, CAGR %) and Market Shares (%) by Drug Class, 2013, 2018 and 2024
Table 11.2 The World Antiemetic Drugs Market: Revenue Forecasts ($m, AGR %, CAGR %) and Market Shares (%) by Region, 2013, 2018 and 2024


List of Figures
Figure 3.1 The Global Antiemetic Drug Market: Revenue ($m) by Drug Class, 2013
Figure 3.2 The Global Antiemetic Drug Market: Market Shares (%) by Drug Class, 2013
Figure 3.3 Leading Antiemetic Drugs: Market Share (%) by Drug, 2013
Figure 3.4 The Global Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 3.5 The Global Antiemetic Drug Market: Drivers and Restraints, 2014-2024
Figure 3.6 The Global Antiemetic Drug Market: Market Shares (%) by Drug Class, 2018
Figure 3.7 The Global Antiemetic Drug Market: Revenue Shares (%) by Drug Class, 2024
Figure 4.1 The 5-HT3 Antagonists Drug Market: Revenue ($m) by Leading Drug, 2013
Figure 4.2 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Leading Drug, 2013
Figure 4.3 The 5-HT3 Antagonists Drug Market: Revenue Forecast ($m), 2014-2024
Figure 4.4 Palonosetron: Revenue Forecast ($m), 2014-2024
Figure 4.5 Ondansetron: Revenue Forecast ($m), 2014-2024
Figure 4.6 Granisetron: Revenue Forecast ($m), 2014-2024
Figure 4.7 Dolasetron: Revenue Forecast ($m), 2014-2024
Figure 4.8 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2018
Figure 4.9 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2024
Figure 5.1 The Cannabinoids Drug Market: Revenue ($m) by Leading Drug, 2013
Figure 5.2 The Cannabinoids Drug Market: Market Shares (%) by Leading Drug, 2013
Figure 5.3 The Cannabinoids Drug Market: Revenue Forecast ($m), 2014-2024
Figure 5.4 Dronabinol: Revenue Forecast ($m), 2014-2024
Figure 5.5 Nabilone: Revenue Forecast ($m), 2014-2024
Figure 5.6 The Cannabinoids Drug Market: Market Shares (%) by Drug, 2018
Figure 5.7 The Cannabinoids Drug Market: Market Shares (%) by Drug, 2024
Figure 6.1 The Dopamine Antagonists Drug Market: Revenues ($m) by Leading Drug, 2013
Figure 6.2 The Dopamine Antagonists Drug Market: Market Shares (%) by Leading Drug, 2013
Figure 6.3 The Dopamine Antagonists Drug Market: Revenue Forecast ($m), 2014-2024
Figure 6.4 Metoclopramide: Revenue Forecast ($m), 2014-2024
Figure 6.5 Domperidone: Revenue Forecast ($m), 2014-2024
Figure 6.6 The Dopamine Antagonists Drug Market: Market Shares (%) by Drug, 2018
Figure 6.7 The Dopamine Antagonists Drug Market: Market Shares (%) by Drug, 2024
Figure 7.1 The Global Antiemetic Drug Market: Revenue ($m) by Region, 2013
Figure 7.2 The Global Antiemetic Drug Market: Market Shares (%) by Region, 2013
Figure 7.3 The US Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.4 The EU5 Antiemetic Drug Market: Revenue ($m) by Country, 2013
Figure 7.5 The EU5 Antiemetic Drug Market: Market Shares (%) by Country, 2013
Figure 7.6 The EU5 Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.7 The German Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.8 The French Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.9 The UK Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.10 The Italian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.11 The Spanish Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.12 The Japanese Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.13 The Russian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.14 The Chinese Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.15 The Indian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 7.16 The Brazilian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
Figure 11.1 The Global Antiemetic Drug Market: Revenue Forecasts ($m) by Drug Class, 2013, 2018 and 2024
Figure 11.2 The Global Antiemetic Drug Market: Revenue Forecasts ($m) by Region, 2013, 2018 and 2024

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.